Literature DB >> 34025192

The Combination of Prognostic Nutritional Indicator and Serum Carcinoembryonic Antigen is Useful in Predicting Postoperative Recurrence in Stage II Colorectal Cancer.

Chihiro Uejima1, Hiroaki Saito2, Yoichiro Tada1, Akimitsu Tanio1, Yuki Murakami1, Manabu Yamamoto1, Tomoyuki Matsunaga1, Yoji Fukumoto3, Naruo Tokuyasu1, Shuichi Takano1, Teruhisa Sakamoto1, Soichiro Honjo1, Yoshiyuki Fujiwara1.   

Abstract

BACKGROUND: The efficacy of adjuvant chemotherapy in stage II colorectal cancer (CRC) patients has not been clearly demonstrated. Therefore, identification of robust prognostic factors is crucial for the assessment of recurrence risk in stage II CRC and appropriate adjuvant treatment, in clinical practice.
METHODS: We enrolled 135 colorectal adenocarcinoma patients who underwent proctocolectomies and had histologically diagnosed stage II CRC.
RESULTS: Receiver operating characteristic (ROC) analysis, to evaluate the predictive ability of certain serum factors for CRC recurrence, indicated that the prognostic nutritional indicator (PNI), followed by serum carcinoembryonic antigen (CEA) level, were the strongest predictive metrics. Based on cutoff values from ROC analyses, patients were divided as follows; CEAHigh (≥ 4.55 ng/mL), CEALow (< 4.55 ng/mL), PNIHigh (≥ 47.72), and PNILow (< 47.72). The recurrence rates of patients with CEAHigh and PNILow, CEAHigh and PNIHigh, CEALow and PNILow, and CEALow and PNIHigh were 34.3%, 0%, 6.8%, and 2.6%, respectively (a significant difference at P < 0.0001). Logistic regression analysis revealed that the combination of serum CEA level and PNI was an independent predictive indicator of tumor recurrence after operation in stage II CRC patients. The 5-year disease specific survival rates of patients with CEALowPNIHigh, CEAHighPNIHigh, CEALowPNILow, CEAHighPNILow were 100%, 100%, 97.4%, and 77.5%, respectively (P < 0.0001).
CONCLUSION: The combination of CEA and PNI was useful in predicting postoperative recurrence in stage II CRC patients. ©2021 Tottori University Medical Press.

Entities:  

Keywords:  carcinoembryonic antigen; colorectal cancer; prognosis; prognostic nutritional indicator

Year:  2021        PMID: 34025192      PMCID: PMC8128654          DOI: 10.33160/yam.2021.05.009

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  20 in total

1.  Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators.

Authors:  S Marsoni
Journal:  Semin Oncol       Date:  2001-02       Impact factor: 4.929

2.  Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas.

Authors:  Tsuyoshi Tachibana; Hisashi Onodera; Tatsuaki Tsuruyama; Akira Mori; Satoshi Nagayama; Hiroshi Hiai; Masayuki Imamura
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

3.  A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.

Authors:  Chu Matsuda; Megumi Ishiguro; Satoshi Teramukai; Yoshiki Kajiwara; Shoichi Fujii; Yusuke Kinugasa; Yoshihiko Nakamoto; Masanori Kotake; Yoshiyuki Sakamoto; Kiyotaka Kurachi; Atsuyuki Maeda; Koji Komori; Naohiro Tomita; Yasuhiro Shimada; Keiichi Takahashi; Kenjiro Kotake; Masahiko Watanabe; Hidetaka Mochizuki; Yoko Nakagawa; Kenichi Sugihara
Journal:  Eur J Cancer       Date:  2018-04-17       Impact factor: 9.162

4.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

Authors:  Daniel G Haller; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Frank Gilberg; Karen Rittweger; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

5.  Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma.

Authors:  E J Clark; S Connor; M A Taylor; K K Madhavan; O J Garden; R W Parks
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

6.  Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma.

Authors:  Sunil Saroha; Robert G Uzzo; Elizabeth R Plimack; Karen Ruth; Tahseen Al-Saleem
Journal:  J Urol       Date:  2012-10-04       Impact factor: 7.450

7.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

Authors:  Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

9.  Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer.

Authors:  Jonna Berntsson; Björn Nodin; Jakob Eberhard; Patrick Micke; Karin Jirström
Journal:  Int J Cancer       Date:  2016-05-06       Impact factor: 7.396

10.  Specific carcinoembryonic antigens of the human digestive system.

Authors:  P Gold; S O Freedman
Journal:  J Exp Med       Date:  1965-09-01       Impact factor: 14.307

View more
  1 in total

1.  Preoperative Absolute Lymphocyte Count to Carcinoembryonic Antigen Ratio Is a Superior Predictor of Survival in Stage I to III Colorectal Cancer.

Authors:  Yue Zhou; Fei Cheng; Zihao Zhang; Jia Xiang; Tianhui Xue; Qianwen Ye; Bing Yan
Journal:  Clin Med Insights Oncol       Date:  2022-09-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.